Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination drug consisting of three active ingredients: - **Amoxicillin** is a penicillin-type antibiotic that works by inhibiting bacterial cell wall synthesis, leading to the death of susceptible bacteria. - **Clavulanic acid** is a beta-lactamase inhibitor that prevents certain bacteria from breaking down amoxicillin, thereby extending its antibacterial spectrum. - **Methylprednisolone** is a synthetic glucocorticoid corticosteroid with potent anti-inflammatory and immunosuppressive properties. It acts by modulating gene expression to suppress inflammation and immune responses. This combination may be used in clinical scenarios where both infection (requiring broad-spectrum antibiotic coverage) and significant inflammation (requiring corticosteroid therapy) are present. While combinations of antibiotics with steroids are sometimes used for conditions such as acute sinusitis or exacerbations of chronic obstructive pulmonary disease (COPD), there is limited evidence for the routine use of all three agents together in a single formulation. Each component has distinct mechanisms and indications[2][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amoxicillin + clavulanic acid + methylprednisolone.